Targets and Biomarkers in Cutaneous Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 1420
Special Issue Editors
2. Institute of Molecular Medicine, Medical School Hamburg, Hamburg, Germany
Interests: dermato-oncology; cutaneous lymphoma; malignant melanoma; dermatopathology; clinical trials; targeted therapies; autoimmune diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cutaneous lymphomas are clinically and biologically heterogeneous and have overlapping diagnostic features. With the advance of new technologies and the application of efficient and feasible detection platforms, an unprecedented number of novel biomarkers have been discovered or are under investigation at the genetic, epigenetic, and protein levels and the tumor microenvironment. These biomarkers have enabled new clinical and pathological insights into the mechanisms underlying lymphomagenesis and have also facilitated improvements in the potential of personalized therapy for cutaneous lymphoma patients. However, integrating these biomarkers into clinical practice effectively and precisely in daily practice is challenging. More in-depth studies are required to further validate these novel biomarkers and to assess other parameters that can affect the reproducibility of these biomarkers, such as the selection of detection methods, biological reagents, and interpretation of data.
Despite these challenges, there are many reasons to be optimistic that novel biomarkers will facilitate better algorithms and strategies as we enter a new era of precision medicine to better refine diagnosis, prognostication, and rational treatment design for patients with lymphomas.
This Special Issue welcomes works regarding biomarkers related to alterations in cutaneous lymphomas at the genetic, epigenetic, protein levels, and the tumor microenvironment.
Prof. Dr. Chalid Assaf
Dr. Gabor Dobos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cutaneous T cell lymphoma (CTCL)
- biomarker
- targets
- diagnostics
- personalized medicine
- mycosis fungoides
- Sézary syndrome
- genetics
- epigenetics
- tumor microenvironment